Immunocore Q1 KIMMTRAK sales $70.3M (+36% YoY); brenetafusp ASCO data; cash $832.8M

Immunocore Holdings plc

2024-Q1 EPS reported -$0.49 revenue$70,502,000

KIMMTRAK net sales $70.3M, up 36% YoY; US $50.0M, Europe $19.0M, international $1.4M.
Net loss $24.4M ($0.49/sh) vs $19.4M ($0.40/sh) in Q1 2023; R&D $57.5M, SG&A $39.3M.
Cash $832.8M as of Mar 31, 2024, including $390.2M net from Feb 2024 convertible notes; plans to repay $50M loan.
Brenetafusp Phase 1/2 data in late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (May 31).
KIMMTRAK launched in 7 additional countries since Jan 2024; now in 17 countries.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Immunocore Holdings plc reported the first quarter ended March 31, 2024 results: revenue Total net product revenue ... was $70.3 million in the first quarter of 2024, net income Net loss for the first quarter of 2024 was $24.4 million, EPS The first quarter basic and diluted loss per share was $0.49.

Period: the first quarter ended March 31, 2024
Revenue: Total net product revenue ... was $70.3 million in the first quarter of 2024
Net income: Net loss for the first quarter of 2024 was $24.4 million
EPS: The first quarter basic and diluted loss per share was $0.49
Result: reported results

Exact text from the filing

On May 8, 2024, Immunocore Holdings plc (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024, as well as other recent corporate updates.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Immunocore Holdings plc filing history →

Source: SEC EDGAR

accession 0001140361-24-024789

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.